Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

127.29 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,886
Open 127.29
Bid (Size) 127.69 (2)
Ask (Size) 127.75 (2)
Prev. Close 127.29
Today's Range 127.29 - 127.29
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill

Performance

YTD
+24.66%
+24.66%
1 Month
-0.13%
-0.13%
3 Month
+8.23%
+8.23%
6 Month
+25.17%
+25.17%
1 Year
+51.14%
+51.14%

More News

Read More
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Via MarketBeat
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
Via Benzinga
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
Via The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
Via The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
Via InvestorPlace
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
Via Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Via InvestorPlace
This Is a Huge Sigh of Relief for Novo Nordisk Investors
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Via Benzinga
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target
Via Investor's Business Daily
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Via Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
Via InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
Via InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
Via Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
Via The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
Via InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.